Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AEON NASDAQ:HOOK NASDAQ:PRFX NASDAQ:SNPX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAEONAEON Biopharma$1.13+9.7%$0.78$0.38▼$83.52$13.16M0.741.37 million shs1.12 million shsHOOKHOOKIPA Pharma$0.90-3.7%$0.90$0.72▼$4.32$10.92M1.04105,645 shs8,467 shsPRFXPainReform$1.31-8.7%$1.45$1.24▼$16.63$2.63M0.58161,299 shs261,701 shsSNPXSynaptogenix$6.89-2.8%$6.61$1.84▼$7.85$9.58M1.08250,819 shs547,945 shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAEONAEON Biopharma0.00%+40.02%+44.87%+35.41%-98.42%HOOKHOOKIPA Pharma0.00%-3.55%-3.49%-25.33%-75.85%PRFXPainReform0.00%-5.43%-8.10%-6.79%-44.04%SNPXSynaptogenix0.00%+7.49%+11.85%-23.36%+132.77%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAEONAEON Biopharma$1.13+9.7%$0.78$0.38▼$83.52$13.16M0.741.37 million shs1.12 million shsHOOKHOOKIPA Pharma$0.90-3.7%$0.90$0.72▼$4.32$10.92M1.04105,645 shs8,467 shsPRFXPainReform$1.31-8.7%$1.45$1.24▼$16.63$2.63M0.58161,299 shs261,701 shsSNPXSynaptogenix$6.89-2.8%$6.61$1.84▼$7.85$9.58M1.08250,819 shs547,945 shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAEONAEON Biopharma0.00%+40.02%+44.87%+35.41%-98.42%HOOKHOOKIPA Pharma0.00%-3.55%-3.49%-25.33%-75.85%PRFXPainReform0.00%-5.43%-8.10%-6.79%-44.04%SNPXSynaptogenix0.00%+7.49%+11.85%-23.36%+132.77%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAEONAEON Biopharma 3.00BuyN/AN/AHOOKHOOKIPA Pharma 2.33Hold$4.50402.23% UpsidePRFXPainReform 1.50ReduceN/AN/ASNPXSynaptogenix 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest PRFX, HOOK, AEON, and SNPX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/8/2025AEONAEON BiopharmaAegisSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy10/8/2025PRFXPainReformWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025PRFXPainReformWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)(Data available from 10/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAEONAEON BiopharmaN/AN/AN/AN/A($4.12) per shareN/AHOOKHOOKIPA Pharma$9.35M1.17N/AN/A$4.25 per share0.21PRFXPainReformN/AN/AN/AN/A$2.08 per shareN/ASNPXSynaptogenixN/AN/AN/AN/A$4.33 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAEONAEON Biopharma-$36.63M-$6.086.28N/AN/AN/AN/A-994.63%11/12/2025 (Estimated)HOOKHOOKIPA Pharma-$43.50M-$4.73N/AN/AN/A-785.66%-120.09%-77.14%11/12/2025 (Estimated)PRFXPainReform-$14.59M-$147.33N/A∞N/AN/AN/AN/AN/ASNPXSynaptogenix-$12.77M-$10.08N/A∞N/AN/A-115.28%-58.31%N/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAEONAEON BiopharmaN/AN/AN/AN/AN/AHOOKHOOKIPA PharmaN/AN/AN/AN/AN/APRFXPainReformN/AN/AN/AN/AN/ASNPXSynaptogenixN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAEONAEON BiopharmaN/A0.220.22HOOKHOOKIPA PharmaN/A3.613.61PRFXPainReformN/A1.59N/ASNPXSynaptogenixN/A72.5972.59Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAEONAEON Biopharma22.78%HOOKHOOKIPA Pharma63.88%PRFXPainReform37.28%SNPXSynaptogenix10.34%Insider OwnershipCompanyInsider OwnershipAEONAEON Biopharma0.86%HOOKHOOKIPA Pharma3.30%PRFXPainReform34.40%SNPXSynaptogenix2.73%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAEONAEON Biopharma511.64 million74.37 millionNot OptionableHOOKHOOKIPA Pharma16012.19 million11.79 millionOptionablePRFXPainReform42.01 million1.32 millionNot OptionableSNPXSynaptogenix41.39 million1.35 millionNot OptionablePRFX, HOOK, AEON, and SNPX HeadlinesRecent News About These CompaniesSynaptogenix (NASDAQ:SNPX) Shares Down 6.4% - Time to Sell?October 9, 2025 | americanbankingnews.comTAO Synergies (Formerly Synaptogenix) Begins Trading Under New Nasdaq Stock Symbol "TAOX" Effective at Market Open TodayJuly 1, 2025 | prnewswire.comSynaptogenix Announces Name Change to TAO Synergies and New Ticker Symbol "TAOX" for Alignment with AI-Focused Crypto Treasury StrategyJune 26, 2025 | prnewswire.comSynaptogenix Announces Initial TAO Acquisition under Crypto Treasury Strategy, Appoints BitGo as Custodian, and Commences Yield Generation Through Staking - KXAN AustinJune 26, 2025 | kxan.comKSynaptogenix begins TAO acquisition as part of crypto treasury strategyJune 26, 2025 | uk.investing.comSynaptogenix Announces Initial TAO Acquisition under Crypto Treasury Strategy, Appoints BitGo as Custodian, and Commences Yield Generation Through Staking - KTLAJune 26, 2025 | ktla.comKSynaptogenix Announces Initial TAO Acquisition under Crypto Treasury Strategy, Appoints BitGo as Custodian, and Commences Yield Generation Through StakingJune 24, 2025 | prnewswire.comSynaptogenix Unveils TAO-Focused Crypto Treasury PlanJune 10, 2025 | livebitcoinnews.comLSynaptogenix Appoints Crypto Expert to Lead Digital Asset Treasury Strategy Focused Exclusively on Top-Valued AI TokenJune 9, 2025 | prnewswire.comSynaptogenix Inc Ordinary SharesJanuary 3, 2025 | morningstar.comMSynaptogenix Board of Directors Forms Special Committee to Explore Value Creation Opportunities Utilizing Balance Sheet StrengthDecember 20, 2024 | prnewswire.comSynaptogenix (NASDAQ:SNPX) Stock Quotes, Forecast and News SummaryOctober 7, 2024 | benzinga.comSynaptogenix secures $5 million in preferred stock financingSeptember 13, 2024 | investing.comSynaptogenix Announces $5.0 Million FinancingSeptember 11, 2024 | prnewswire.comSNPX Stock Earnings: Synaptogenix Reported Results for Q2 2024August 16, 2024 | investorplace.comSynaptogenix Partners With LSU Health New Orleans To Study PUFA Analogs To Treat Spinal Cord InjuryJuly 19, 2024 | markets.businessinsider.comSynaptogenix Announces New Collaboration with LSU Health New Orleans for Study of Proprietary Analogs in Spinal Cord InjuryJuly 18, 2024 | prnewswire.comSynaptogenix Announces FDA Authorization of IND Application for Clinical Trial for Bryostatin-1 in Multiple SclerosisJune 26, 2024 | prnewswire.comSNPX Stock Earnings: Synaptogenix Reported Results for Q1 2024May 20, 2024 | investorplace.comSynaptogenix Applauds DEA Proposal to Reclassify Cannabis and Shares Expected Benefits to Cannasoul for Cannabinoid-Based Drug DiscoveryMay 7, 2024 | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePRFX, HOOK, AEON, and SNPX Company DescriptionsAEON Biopharma NASDAQ:AEON$1.13 +0.10 (+9.71%) Closing price 10/10/2025 04:00 PM EasternExtended Trading$1.18 +0.06 (+4.87%) As of 08:46 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine, as well as develops ABP-450 for the treatment of gastroparesis and posttraumatic stress disorder. The company is based in Irvine, California.HOOKIPA Pharma NASDAQ:HOOK$0.90 -0.03 (-3.66%) As of 10/10/2025 03:56 PM EasternHOOKIPA Pharma Inc., a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in preclinical studies for the treatment of human papillomavirus-positive cancers. The company has a collaboration with Gilead Sciences, Inc. to develop arenavirus based therapeutics to treat hepatitis B virus and human immunodeficiency virus infections. HOOKIPA Pharma Inc. was founded in 2011 and is headquartered in New York, New York.PainReform NASDAQ:PRFX$1.30 -0.13 (-8.74%) Closing price 10/10/2025 04:00 PM EasternExtended Trading$1.36 +0.06 (+4.21%) As of 08:21 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.PainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and second trial for pain treatment of hernia repair operations. The company was incorporated in 2007 and is based in Tel Aviv, Israel.Synaptogenix NASDAQ:SNPX$6.89 -0.20 (-2.82%) As of 10/10/2025Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. The company focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. It also evaluates therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. The company was incorporated in 2012 and is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Broadcom Gets Second $420 Target as CPO Win Boosts Outlook AST SpaceMobile's Big Win: Shares Soar on New Deal With Verizon Microsoft 365 Premium Marks the Next Phase of AI Monetization 3 Reasons to Buy Sprouts Farmers Market Ahead of Earnings Bassett Furniture: Buy Now, Sit Back, and Collect Dividends Why Amazon’s Prime Day May Be the Catalyst for a Year-End Rally PepsiCo’s Deep Discount Will Soon Evaporate: Buy It While You Can Bargain Alert: DraftKings Is the Most Oversold It’s Ever Been Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
